Prevalence of Type 2 Diabetes Mellitus and Dyslipidemia in Patients with Cryptogenic Cirrhosis: a Hospital-Based Study
Abstract
Background: Liver cirrhosis is the end stage of liver disease that is caused by various etiologies. Type 2 diabetes mellitus (T2DM), dyslipidemia and obesity are the most common situations that are seen together with non-alcoholic steatohepatitis (NASH), which is frequently asymptomatic and can silently lead to cirrhosis. There are some studies suggesting that NASH might be one of the underlying causes of cryptogenic cirrhosis (CC). Materials and Methods: Two hundred twenty six cirrhotic patients registered in transplantation unit of Namazi Hospital of Shiraz University of Medical Sciences from January 2006 to the last day of June 2014 were selected in two groups of CC and non-CC patients. Age, sex, weight, child class of cirrhosis and presence of T2DM, dyslipidemia and lipid profile were extracted from their records. Results: There was significant difference between prevalence of T2DM and FBS levels among CC and non-CC subjects (P <0.01). Prevalence of T2DM in CC group (38.9%) was more than two times higher than non-CC group (18.6%). On the contrary, the differences between prevalence of dyslipidemia and its laboratory characteristics such as total cholesterol, TG, HDL and LDL were insignificant among both groups (P >0.05). Conclusion: Results showed a higher prevalence of T2DM in subjects with CC but there are some doubts about T2DM being one of the risk factors of CC. Dyslipidemia and its components including TG, LDL, HDL and total cholesterol were not significantly different in CC and non-CC subjects.[GMJ. 2015;4(3):112-16]References
Kodali VP, Gordon SC, Silverman AL, McCray DG. Cryptogenic liver disease in the United States: further evidence for non-A, non-B, and non-C hepatitis. The American journal of gastroenterology. 1994;89(10):1836-9.
Greeve M, Ferrell L, Kim M, Combs C, Roberts J, Ascher N, et al. Cirrhosis of undefined pathogenesis: absence of evidence for unknown viruses or autoimmune processes. Hepatology (Baltimore, Md). 1993;17(4):593-8.
Ayata G, Gordon FD, Lewis WD, Pomfret E, Pomposelli JJ, Jenkins RL, et al. Cryptogenic cirrhosis: clinicopathologic findings at and after liver transplantation. Human pathology. 2002;33(11):1098-104.
Uchida T, Shimojima M, Gotoh K, Shikata T, Tanaka E, Kiyosawa K. "Silent" hepatitis B virus mutants are responsible for non-A, non-B, non-C, non-D, non-E hepatitis. Microbiology and immunology. 1994;38(4):281-5.
Kaymakoglu S, Cakaloglu Y, Demir K, Turkoglu S, Badur S, Gurel S, et al. Is severe cryptogenic chronic hepatitis similar to autoimmune hepatitis? Journal of hepatology. 1998;28(1):78-83.
Alter MJ, Hadler SC, Judson FN, Mares A, Alexander WJ, Hu PY, et al. Risk factors for acute non-A, non-B hepatitis in the United States and association with hepatitis C virus infection. Jama. 1990;264(17):2231-5.
Koretz RL, Abbey H, Coleman E, Gitnick G. Non-A, non-B post-transfusion hepatitis. Looking back in the second decade. Annals of internal medicine. 1993;119(2):110-5.
Hickman IJ, Macdonald GA. Impact of diabetes on the severity of liver disease. Am J Med. 2007;120(10):829-34.
Bacon BR, Farahvash MJ, Janney CG, Neuschwander-Tetri BA. Nonalcoholic steatohepatitis: an expanded clinical entity. Gastroenterology. 1994;107(4):1103-9.
Poonawala A, Nair SP, Thuluvath PJ. Prevalence of obesity and diabetes in patients with cryptogenic cirrhosis: a case-control study. Hepatology (Baltimore, Md). 2000;32(4 Pt 1):689-92.
Kojima H, Sakurai S, Matsumura M, Umemoto N, Uemura M, Morimoto H, et al. Cryptogenic cirrhosis in the region where obesity is not prevalent. World journal of gastroenterology : WJG. 2006;12(13):2080-5.
Siriwardana RC, Niriella MA, Liyanage CA, Wijesuriya SR, Gunathilaka B, Dassanayake AS, et al. Cryptogenic cirrhosis is the leading cause for listing for liver transplantation in Sri Lanka. Indian journal of gastroenterology : official journal of the Indian Society of Gastroenterology. 2013;32(6):397-9.
Dassanayake AS, Kasturiratne A, Rajindrajith S, Kalubowila U, Chakrawarthi S, De Silva AP, et al. Prevalence and risk factors for non-alcoholic fatty liver disease among adults in an urban Sri Lankan population. Journal of gastroenterology and hepatology. 2009;24(7):1284-8.
Caldwell SH, Oelsner DH, Iezzoni JC, Hespenheide EE, Battle EH, Driscoll CJ. Cryptogenic cirrhosis: clinical characterization and risk factors for underlying disease. Hepatology (Baltimore, Md). 1999;29(3):664-9.
Petit JM, Hamza S, Rollot F, Sigonney V, Crevisy E, Duvillard L, et al. Impact of liver disease severity and etiology on the occurrence of diabetes mellitus in patients with liver cirrhosis. Acta diabetologica. 2014;51(3):455-60.
Tellez-Avila FI, Sanchez-Avila F, Garcia-Saenz-de-Sicilia M, Chavez-Tapia NC, Franco-Guzman AM, Lopez-Arce G, et al. Prevalence of metabolic syndrome, obesity and diabetes type 2 in cryptogenic cirrhosis. World journal of gastroenterology : WJG. 2008;14(30):4771-5.
Authors who publish with this journal agree to the following terms:
- Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution 4.0 International License that allows others to share the work with an acknowledgment of the work's authorship and initial publication in this journal.
- Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgment of its initial publication in this journal.
- Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).
